SCHEMBL18233459

SCHEMBL18233459

O=S(=O)(Cl)c1cc2c(F)cccc2o1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CCR2 P41597 1/20 0.37
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CA2 P00918 2/20 0.35
AR P10275 3/20 0.35
F2RL3 Q96RI0 1/20 0.34
NMUR2 Q9GZQ4 2/20 0.33
GABRP O00591 2/20 0.33
GABRD O14764 2/20 0.33
GABRA1 P14867 2/20 0.33
GABRB1 P18505 2/20 0.33
GABRG2 P18507 2/20 0.33
GABRB3 P28472 2/20 0.33
GABRA5 P31644 2/20 0.33
GABRA3 P34903 2/20 0.33
GABRA2 P47869 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16985244 0.83 MKNK1 (0.38) NPC1HPGDRAB9ASMN1; SMN2CCR2
SCHEMBL8799954 0.79 CA2 (0.39) NPC1HPGDRAB9ASMN1; SMN2MEN1
SCHEMBL8799649 0.74 AHR (0.41) NPC1RAB9ASMN1; SMN2KMT2ACA2
SCHEMBL8797911 0.72 CA2 (0.54) CCR2CA2ARF2RL3PKM
SCHEMBL720789 0.71 CA2 (0.67) HPGDSMN1; SMN2CCR2CA2CA12
SCHEMBL9063028 0.71 CA2 (0.67) HPGDSMN1; SMN2CCR2CA2CA12
SCHEMBL2097841 0.68 NPC1 (0.39) NPC1HPGDRAB9ASMN1; SMN2AR
SCHEMBL12728518 0.68 CYP1A1 (0.40) NPC1HPGDRAB9ASMN1; SMN2AR
SCHEMBL17193877 0.68 NPC1 (0.36) NPC1HPGDRAB9ASMN1; SMN2MEN1
SCHEMBL16686379 0.68 CYP2A6 (0.52) NPC1HPGDRAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108602807-B Heterocyclic sulfonamide derivatives and drugs containing the same EA制药株式会社 2022-05-13 CN disclosed
EP-3412664-B1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE CONTAINING SAME EA PHARMA CO LTD (JP) 2022-03-30 EP disclosed
US-10626112-B2 Heterocyclic sulfonamide derivative and medicine comprising same EA PHARMA CO., LTD. (JP) 2020-04-21 US disclosed
US-10584116-B2 Heterocyclic sulfonamide derivative and medicine containing same EA PHARMA CO., LTD. (JP) 2020-03-10 US disclosed
US-20190023699-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE CONTAINING SAME EA PHARMA CO., LTD. (JP) 2019-01-24 US disclosed
US-20190023699-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE CONTAINING SAME EA PHARMA CO., LTD. (JP) 2019-01-24 US disclosed
EP-3412664-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE CONTAINING SAME EA Pharma Co., Ltd. (JP) 2018-12-12 EP disclosed
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME EA PHARMA CO., LTD. (JP) 2016-11-17 US disclosed
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME EA PHARMA CO., LTD. (JP) 2016-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190023699-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE CONTAINING SAME TRPA1, TRPV1, TRPV2 NPC1 676/4885HPGD 769/4885RAB9A 3409/4885
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME TRPA1, TRPV1, TRPV2 NPC1 705/4885HPGD 853/4885RAB9A 3760/4885
US-10626112-B2 Heterocyclic sulfonamide derivative and medicine comprising same TRPA1, TRPV1, TRPV2 NPC1 705/4885HPGD 853/4885RAB9A 3760/4885
US-10584116-B2 Heterocyclic sulfonamide derivative and medicine containing same TRPA1, TRPV1, TRPV2 NPC1 676/4885HPGD 769/4885RAB9A 3409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.